Moore Capital Management LP Makes New Investment in Zimmer Biomet Holdings, Inc. $ZBH

Moore Capital Management LP purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, HoldingsChannel.com reports. The fund purchased 198,642 shares of the medical equipment provider’s stock, valued at approximately $17,101,000.

A number of other large investors have also recently bought and sold shares of the company. Dodge & Cox boosted its position in shares of Zimmer Biomet by 1.3% during the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock worth $2,113,736,000 after acquiring an additional 290,676 shares in the last quarter. BlackRock Inc. acquired a new position in Zimmer Biomet during the second quarter valued at approximately $1,344,282,000. State Street Corp raised its position in Zimmer Biomet by 2.3% during the fourth quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock valued at $795,814,000 after purchasing an additional 195,214 shares in the last quarter. Franklin Resources Inc. lifted its stake in Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after purchasing an additional 2,017,857 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Zimmer Biomet by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider’s stock worth $468,821,000 after purchasing an additional 36,611 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Canaccord Genuity Group lifted their target price on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research report on Monday, August 10th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Stifel Nicolaus raised their target price on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 25th. Finally, UBS Group reissued a “buy” rating and set a $120.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $101.10 on Monday. The company has a market capitalization of $19.28 billion, a PE ratio of 24.60, a P/E/G ratio of 2.74 and a beta of 0.45. The company has a 50 day simple moving average of $93.88 and a two-hundred day simple moving average of $91.46. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $106.88.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period last year, the company posted $2.07 EPS. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.